In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Moderna Inc (NASDAQ: MRNA) closed the day trading at $60.20 down -1.42% from the previous closing price of $61.07. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 6.2 million shares were traded. MRNA stock price reached its highest trading level at $62.11 during the session, while it also had its lowest trading level at $59.62.
Ratios:
For a better understanding of MRNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On September 13, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $88 to $70.
Jefferies Downgraded its Buy to Hold on September 13, 2024, whereas the target price for the stock was revised from $120 to $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’24 when Klinger Shannon Thyme sold 551 shares for $73.57 per share. The transaction valued at 40,539 led to the insider holds 18,154 shares of the business.
Klinger Shannon Thyme bought 551 shares of MRNA for $40,539 on Sep 09 ’24. On Sep 03 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 114 shares for $76.99 each. As a result, the insider received 8,777 and left with 17,566 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 23140638720 and an Enterprise Value of 15921641472. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.59 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 3.153 whereas that against EBITDA is -3.877.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $61.03. The 50-Day Moving Average of the stock is -25.26%, while the 200-Day Moving Average is calculated to be -42.74%.
Shares Statistics:
Over the past 3-months, MRNA traded about 4.62M shares per day on average, while over the past 10 days, MRNA traded about 4929800 shares per day. A total of 382.00M shares are outstanding, with a floating share count of 342.77M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.97% stake in the company. Shares short for MRNA as of 1726185600 were 27613114 with a Short Ratio of 5.97, compared to 1723680000 on 25003118. Therefore, it implies a Short% of Shares Outstanding of 27613114 and a Short% of Float of 9.45.
